Key Points
- Medpace director Cornelius Mccarthy III sold 1,140 shares for approximately $690,122 at an average price of $605.37, reducing his direct holdings by 8.5% to 12,275 shares.
- Medpace reported quarterly EPS of $4.25, exceeding estimates of $3.98, while revenue rose 17.2% year over year to $707.33 million. The company issued fiscal 2026 EPS guidance of $17.25–$17.95.
- Institutional investors own nearly 78% of Medpace, while analysts maintain a consensus “Hold” rating with an average price target of $584.18.
Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) Director Cornelius Mccarthy III sold 1,140 shares of Medpace stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $605.37, for a total value of $690,121.80. Following the sale, the director directly owned 12,275 shares of the company's stock, valued at approximately $7,430,916.75. This represents a 8.50% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Medpace Stock Performance
Medpace stock opened at $581.95 on Friday. The business's 50-day simple moving average is $533.75 and its two-hundred day simple moving average is $491.74. The company has a market cap of $16.24 billion, a PE ratio of 34.11, a PEG ratio of 2.66 and a beta of 1.15. Medpace Holdings, Inc. has a fifty-two week low of $373.00 and a fifty-two week high of $677.90.
Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The firm had revenue of $707.33 million during the quarter, compared to analysts' expectations of $689.51 million. During the same period last year, the business posted $3.10 earnings per share. The company's revenue for the quarter was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, analysts predict that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.
Hedge Funds Weigh In On Medpace
A number of hedge funds have recently bought and sold shares of MEDP. BlackRock Inc. acquired a new stake in Medpace in the second quarter valued at approximately $1,323,047,000. AQR Capital Management LLC raised its stake in shares of Medpace by 65.1% during the 3rd quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company's stock worth $518,170,000 after buying an additional 404,226 shares during the period. Madison Asset Management LLC purchased a new position in shares of Medpace during the 2nd quarter valued at approximately $128,956,000. Arrowstreet Capital Limited Partnership lifted its position in shares of Medpace by 205.8% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company's stock valued at $161,523,000 after buying an additional 211,411 shares in the last quarter. Finally, Franklin Resources Inc. grew its stake in Medpace by 158.6% in the 4th quarter. Franklin Resources Inc. now owns 299,472 shares of the company's stock valued at $168,198,000 after acquiring an additional 183,645 shares during the period. Hedge funds and other institutional investors own 77.98% of the company's stock.
Wall Street Analysts Forecast Growth
Several analysts have commented on MEDP shares. Jefferies Financial Group cut shares of Medpace from a "buy" rating to a "hold" rating and lifted their price objective for the company from $490.00 to $515.00 in a research note on Tuesday, July 7th. Mizuho increased their price objective on shares of Medpace from $586.00 to $665.00 and gave the stock an "outperform" rating in a research note on Friday, July 24th. Barclays set a $600.00 target price on shares of Medpace in a report on Thursday, July 23rd. TD Cowen boosted their target price on shares of Medpace from $419.00 to $492.00 and gave the company a "hold" rating in a research report on Friday, July 24th. Finally, Leerink Partners set a $620.00 price target on shares of Medpace in a report on Thursday, July 23rd. Three equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $584.18.
Check Out Our Latest Stock Analysis on Medpace
About Medpace
(
Get Free Report)
Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
